<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03109249</url>
  </required_header>
  <id_info>
    <org_study_id>CLR_16_13</org_study_id>
    <nct_id>NCT03109249</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer</brief_title>
  <official_title>Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharma Advanced Research Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharma Advanced Research Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SPARC1613 is chemotherapeutic agent with a wide spectrum of anti-tumor activity. It is used
      extensively in the treatment of advanced carcinomas of the breast, ovaries, lung, and other
      solid tumors.This is pharmacokinetic study of SPARC1613 and Reference1613.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate level of test medication with respect to time in the
      body, and safety when compared with the reference medication Subject will be randomly
      assigned to receive an intravenous infusion of either SPARC1613 delivered over 25 (±1)
      minutes or Reference1613 delivered over 30 (±1) minutes
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 14, 2017</start_date>
  <completion_date type="Actual">October 4, 2018</completion_date>
  <primary_completion_date type="Actual">October 4, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>Pre-dose,post dose upto 3 days</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>First dose of trial drug to one month after last dose.</time_frame>
    <description>Adverse events encountered following dosing with SPARC1613 and Reference1613 will be recorded as per CTCAE4.03</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>Recurrent or Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>SPARC1613</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous administration of SPARC1613</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference 1613</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous administration of Reference1613</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPARC1613</intervention_name>
    <description>Single intravenous infusion of 260 mg/m2 of SPARC1613 delivered over 25 minutes in either of two periods (Period 1 or 2)</description>
    <arm_group_label>Reference 1613</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference1613</intervention_name>
    <description>Single intravenous infusion of 260 mg/m2 of Reference1613 delivered over 30 minutes in either of two periods (Period 1 or 2)</description>
    <arm_group_label>SPARC1613</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject has given written, informed consent and is available for the duration of
             study

          -  Histologically or cytologically confirmed diagnosis of breast cancer

          -  Male or female aged ≥ 18 years

          -  Females subjects of child-bearing potential must have a negative urine pregnancy test

          -  Female subjects must be non-lactating and non-breastfeeding

          -  Subject must be willing and able to comply with scheduled visits, treatment plan and
             laboratory testing

        Exclusion Criteria:

          -  Known hypersensitivity to either of the study drugs or their excipients

          -  Inability to undergo venipuncture and/or tolerate venous access

          -  Pre-existing clinically significant peripheral neuropathy

          -  Positive laboratory exclusion test (HIV, HBsAg, or HCV)

          -  Treatment with investigational agents or participation in clinical trial within 30
             days of study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SPARC Site 40</name>
      <address>
        <city>Visakhapatnam</city>
        <state>Andhra Pradesh</state>
        <zip>530017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 20</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380052</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC site 39</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC site 38</name>
      <address>
        <city>Karamsad</city>
        <state>Gujarat</state>
        <zip>388325</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 27</name>
      <address>
        <city>Surat</city>
        <state>Gujarat</state>
        <zip>395002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 35</name>
      <address>
        <city>Surat</city>
        <state>Gujarat</state>
        <zip>422005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 24</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>391760</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 13</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560027</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC site 41</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560072</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 28</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560090</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 22</name>
      <address>
        <city>Belgaum</city>
        <state>Karnataka</state>
        <zip>590010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 7</name>
      <address>
        <city>Mangalore</city>
        <state>Karnataka</state>
        <zip>5750001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 25</name>
      <address>
        <city>Aurangabad</city>
        <state>Maharashtra</state>
        <zip>431 003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 23</name>
      <address>
        <city>Aurangabad</city>
        <state>Maharashtra</state>
        <zip>431210</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 2</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400022</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 12</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC site 34</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <zip>422004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 37</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <zip>422005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 18</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411 044</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 4</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 9</name>
      <address>
        <city>Aurangabad</city>
        <state>Marashtra</state>
        <zip>431005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 15</name>
      <address>
        <city>Khorda</city>
        <state>Orissa</state>
        <zip>751007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC site 42</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>DrGRaja</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC Site 32</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <zip>625107</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>May 2, 2019</last_update_submitted>
  <last_update_submitted_qc>May 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

